MDxHealth (MDXH) Projected to Post Quarterly Earnings on Wednesday

MDxHealth (NASDAQ:MDXH) is expected to issue its quarterly earnings data after the market closes on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $22.67 million for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

MDxHealth Trading Down 3.2 %

Shares of MDXH stock opened at $1.80 on Tuesday. The company has a market capitalization of $85.12 million, a P/E ratio of -1.18 and a beta of 1.34. MDxHealth has a 12-month low of $1.55 and a 12-month high of $3.85. The company has a quick ratio of 1.45, a current ratio of 1.54 and a debt-to-equity ratio of 3.14. The firm has a 50-day moving average price of $2.03 and a 200 day moving average price of $2.21.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Piper Sandler cut their target price on shares of MDxHealth from $8.00 to $6.00 and set an “overweight” rating for the company in a research note on Thursday, November 7th. Lake Street Capital initiated coverage on MDxHealth in a research report on Thursday, October 31st. They issued a “buy” rating and a $7.00 price objective for the company.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.